All In Biotech

Drug Trial Radar · NCT02109627

Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML

Phase Ib Study of Ficlatuzumab With High Dose Cytarabine (HiDAC) in Relapsed and Refractory AML

Last checked: Nov 20, 2026Latest source record: Mar 24, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

17

Actual

Start

May 1, 2015

Primary completion

Dec 2, 2019

Study completion Dec 2, 2019

Sponsor

Lead sponsor
C. Babis AndreadisAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
AVEO Pharmaceuticals, Inc.; Gateway for Cancer Research
First posted
Apr 10, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to see if ficlatuzumab when combined with cytarabine, a standard treatment for AML, is safe to give to patients and to determine the best dose to give. The study doctors want to see what effects, good and/or bad, the study drug has on subjects and their AML. The study will look at what side effects subjects may have and how subjects feel after receiving the study drug.

Conditions

  • Acute Myeloid Leukemia
  • Relapsed Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia

Interventions

  • FiclatuzumabDrug

    5-20 mg/kg; intravenous; Days 0, 14, 28, and 42. Number of cycles: until progression or unacceptable toxicity develops.

  • CytarabineDrug

    2 g/m2; intravenous; Days 2-7; Number of cycles: until progression or unacceptable toxicity develops.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-Limiting Toxicity (DLT) for ficlatuzumab when administered with HiDACTime frame: Up to 2 years
  2. Maximum Tolerated Dose (MTD) for ficlatuzumab when administered with HiDACTime frame: Up to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of California, San Francisco

    San Francisco, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.